Galimedix completes phase 1 study with oral small molecule GAL-101
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Subscribe To Our Newsletter & Stay Updated